They say all good things must come to an end, and I’m sad to say this will be my last issue at PharmaTimes – though I’m leaving the magazine in very capable hands with the existing PT team, including long-time news editor Selina, who will be taking over the editor role soon!
2018 has been one of the most interesting years I can remember since starting in the pharma industry, so it seems fitting for my final issue to take a look at the biggest stories of the past year with some of PT’s best writers.
This year the industry has faced some amazing advances that we could only have dreamed about a few years ago – from AI to 3D printed drugs and nanorobots – as well as some old stalwart issues like NHS challenges, controversial patent cases and big M&A deals. We analyse all of these starting on p16.
Elsewhere in the magazine we take a look at a potential new avenue to prevent the devastating graft versus host disease (p38) and ask some sales experts how pharma can best work with CSOs (p32).
I hope you’ve enjoyed the issues over the last couple of years, and will continue to enjoy them in the future (I’m certainly looking forward to becoming a PT reader!).
